Research programme: small molecule therapeutics - Merck Serono/SGX Pharmaceuticals
Alternative Names: Small molecule therapeutics - Merck Serono/Structural GenomiXLatest Information Update: 06 Oct 2010
Price :
$50 *
At a glance
- Originator Merck Serono; SGX Pharmaceuticals
- Class Small molecules
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Unspecified
Most Recent Events
- 06 Oct 2010 Discontinued - Preclinical for Undefined indication in USA (unspecified route)
- 08 Jan 2007 Serono is now called Merck Serono
- 05 Jan 2007 Serono has been acquired by Merck KGaA